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Irene K Louh1,2 and William D Freeman3,4,5*Synthetic cannabinoids, often sold under labels such as
'spice', are a popular product sold in incense shops and
on the internet. When inhaled, consumers often report
experiences similar to marijuana use, thus making synthetic
cannabinoids a popular street substitute for marijuana.
With increasing use, the number of patients presenting to
emergency departments due to the toxic effects of these
products has increased. While many reported side effects,
including anxiety, agitation, tachycardia, and hypertension
[1,2], are transient and relatively mild, reports of more
severe consequences, including psychosis and seizures,
are increasing [2,3] with ICU admissions.
Spice is often sold as 'incense' in tobacco shops and
because of such is not under federal regulations for
human consumption (Figure 1 shows the disclaimer on the
packaging that it is not to be used for human consump-
tion). According to data from the National Poison Data
System, 3.8% of calls regarding intoxication from synthetic
cannabinoids in 2010 reported seizures [3], and in 2013,
there were 2,613 calls to poison control centers for
synthetic cannabinoid exposure [4]. We find that spice
intoxication is challenging to diagnose clinically because
the features mimic serotonin syndrome. For example, we
recently saw a case of 'spice encephalopathy' that presen-
ted as a first-onset seizure but had features of serotonin
syndrome (myoclonus, dilated pupils). However, serotonin
syndrome and spice intoxication have signs and symptoms
that may overlap with other toxic drug ingestion states.
Further, when reviewing the literature on ‘spice', we found
eight other discrete cases demonstrating seizure post-
'spice' inhalation. In all reported cases, toxicology screens
for cannabis are negative, such as ours was. This is, in fact,
to be expected with synthetic cannabinoid intoxication
and part of the diagnostic dilemma. All reported cases of
spice intoxication are similar in that seizure may manifest
within a few hours after smoking the synthetic cannabinoid.* Correspondence: Freeman.william1@mayo.edu
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article, unless otherwise stated.In addition, some patients require intubation and mechan-
ical ventilation requiring ICU admission, but most recover
quickly. Our patient’s case was admitted to the ICU after a
bag of synthetic spice was noticed along with a partially
smoked ‘spice cigarette’, which confirmed the diagnosis. As
signs/symptoms can be similar to serotonin syndrome, it is
important to review carefully the medical history and medi-
cations or historians who find such patients since they may
not be able to provide a history themselves. A high degree
of clinical suspicion of this drug is required, and discovery
of the smoking material (Figure 1) as in our case can greatly
aid in the clinical diagnosis until more accurate labo-
ratory methods can confirm this toxic substance in
toxicology tests.
'Spice' or synthetic cannabinoid-induced toxicity is an
emerging etiology of new-onset seizure and does not
appear on conventional drug screens. We feel it is im-
portant for critical care providers to be aware of this
product in order to recognize and appropriately treat
this toxicity with supportive management until symptoms
resolve. Obtaining additional history about smoking these
substances can be helpful in making a clinical diagno-
sis until more widespread laboratory testing becomes
available.
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Figure 1 Spice packaging. Image of 'spice' incense packaging. Note the description of 'fragrant potpourri' and 'not for human consumption'
on packaging.
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